Jianpo Lian
Overview
Explore the profile of Jianpo Lian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang H, Jiang S, Luo H, Zhou F, He D, Ma L, et al.
Signal Transduct Target Ther
. 2024 Dec;
9(1):351.
PMID: 39690158
The randomized phase 3 CHART trial (NCT03520478) revealed that rezvilutamide (REZ) plus androgen deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) significantly enhanced radiographic progression-free and overall survival...
2.
Bian X, Gu W, Zhang X, Xie L, Wang S, Shi B, et al.
Med
. 2024 Oct;
6(2):100520.
PMID: 39419035
Background: This exploratory analysis of the CHART trial (ClinicalTrials.gov: NCT03520478) investigated prostate-specific antigen (PSA) kinetics and the correlation between PSA and survival outcomes in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC)....
3.
Wei M, Liu R, Xu Y, Chen X, Liu C, Bai X, et al.
BMC Med
. 2024 Sep;
22(1):365.
PMID: 39232761
Background: Chemotherapy remains the standard first-line treatment for pancreatic adenocarcinoma, but with limited efficacy. We aimed to explore the feasibility of adding the PARP inhibitor fuzuloparib to mFOLFIRINOX in the...
4.
Lian J, Xu C, Chen X, Huang S, Wu D
J Cancer Res Clin Oncol
. 2022 Mar;
148(7):1627-1640.
PMID: 35322299
Purpose: Prostate cancer (PCa) is a leading cause of morbidity and mortality in males. Epigenetic modifier abnormalities are becoming a driving event in PCa. The specific role of KMT2C, a...
5.
Hou Z, Yang T, Mei Z, Zhang S, Gao Y, Chen X, et al.
J Steroid Biochem Mol Biol
. 2021 Mar;
210:105859.
PMID: 33677016
Androgens are essential for prostate cancer development. However, steroidogenesis has mainly been investigated in a limited number of prostate cancer cell lines, leading to varied conclusions and elusive clinical significance....
6.
Lin D, Meng L, Xu F, Lian J, Xu Y, Xie X, et al.
Oncol Rep
. 2017 Oct;
38(5):3160-3166.
PMID: 29048679
Malignant pheochromocytoma (PHEO) is diagnosed only when metastasis has occurred, making it less likely for patients to obtain the benefits of traditional chemotherapy. Anti-oncogene TP53 mutation has been detected in...
7.
Lin D, Li X, Xu L, Lian J, Xu Y, Meng L, et al.
Am J Transl Res
. 2017 Oct;
9(9):3990-4002.
PMID: 28979675
Malignant pheochromocytoma is accurately diagnosed only at occurrence of metastatic foci. However, at that time, patients are less likely to get many benefits from traditional chemotherapy. Over-expression of BCL-2 family...
8.
Lian J, Lin D, Xie X, Xu Y, Xu L, Meng L, et al.
Onco Targets Ther
. 2017 May;
10:2219-2226.
PMID: 28458565
Purpose: Malignant pheochromocytoma (PCC) is a rare tumor with a very poor prognosis and no effective treatments. The aim of this study was to assess the efficacy of a novel...
9.
Xu L, Qi Y, Xu Y, Lian J, Wang X, Ning G, et al.
Oncotarget
. 2016 Apr;
7(24):36235-36246.
PMID: 27105537
Purpose: Adrenocortical carcinoma (ACC) is a rare tumor with very poor prognosis and no effective treatment. The aim of this study was to explore a novel therapy co-targeting EGFR and...